Cybin (CYBN) said Thursday that contract drug manufacturer Thermo Fisher Scientific (TMO) will provide capsule clinical supply for CYB003, Cybin's deuterated psilocin program in late-stage development for the adjunctive treatment of major depressive disorder or MDD.
The clinical-stage company said Thermo Fisher will also support potential commercial manufacturing for CYB003.
Cybin said production of both the drug substance and the drug product will be performed at Thermo Fisher's US pharma services manufacturing sites.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.